Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- None.
- None.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer, a program in HER2 Exon 20 insertion-positive cancers, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302020634.html
SOURCE Nuvalent, Inc.
FAQ
What is the latest announcement from Nuvalent, Inc. (NUVL)?
When and where will the presentation take place?
Where can investors watch the live webcast of the presentation?
How long will the webcast be available for viewing after the presentation?
